Evidence mapPaperPMID 41596244Full record

ReviewInternational journal of molecular sciences2026

Cholesterol Metabolism: An Ally in the Development and Progression of Cervical Cancer.

Imelda Martínez-Ramírez, J Omar Muñoz-Bello, Adriana Contreras-Paredes, Elías Parra-Hernández, Adela Carrillo-García, Marcela Lizano

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Imelda Martínez-RamírezSubdirección de Investigación Básica, Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
J Omar Muñoz-BelloSubdirección de Investigación Básica, Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0002-6809-0212
Adriana Contreras-ParedesSubdirección de Investigación Básica, Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Elías Parra-HernándezGerencia de Análisis y Desarrollo de Pruebas Biológicas, Comisión de Control Analítico y Ampliación de Cobertura (CCAYAC)-Comisión Federal para la Protección Contra Riesgos Sanitarios (COFEPRIS), Mexico City 14050, Mexico.
Adela Carrillo-GarcíaSubdirección de Investigación Básica, Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Marcela LizanoSubdirección de Investigación Básica, Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0002-7553-2541

Funding

Instituto Nacional de Cancerología (015/039/IBI) (CEI/998/15)Instituto Nacional de Cancerología (024/019/IBI) (CEI/025/24)Secretaría de Ciencia, Humanidades, Tecnología e Innovación CF-2023-I-2402Secretaría de Ciencia, Humanidades, Tecnología e Innovación PRONAII-7-Virus y Cáncer 303044
6 · The paper itself

Abstract

Despite screening programs and vaccination campaigns, cervical cancer (CC) remains a health problem worldwide. The involvement of the E6 and E7 oncoproteins of Human Papillomavirus (HPV) is crucial for the development and progression of this type of cancer. Metabolic reprogramming by cancer cells has gained relevance in the last decade due to its ability to promote cell growth, survival, invasion, metastasis, and resistance to therapy. In this review, we focus on alterations in cholesterol metabolism that significantly influence the development and progression of CC, as well as the clinical outcome of patients. Furthermore, evidence from comprehensive omics studies suggesting that E6 and E7 are involved in the exacerbation of elements related to cholesterol metabolism is analyzed. Preclinical and clinical studies are also discussed that demonstrate that cholesterol metabolism is a potential therapeutic target, highlighting its impact on reducing tumor growth, altering the tumor microenvironment, and improving antitumor immunity.

Indexed as

CholesterolUterine Cervical NeoplasmsAnimalsDisease ProgressionFemaleHuman Papillomavirus VirusesHumansMetabolic ReprogrammingOncogene Proteins, ViralPapillomavirus InfectionsTumor MicroenvironmentCholesterolOncogene Proteins, Viralbiomarkerscervical cancercholesterol metabolismHPV oncoproteinsHuman Papillomavirustherapeutic approaches

Identifiers

PMID41596244
PMCPMC12840697

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.